Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation.
Aznab M et al. Asia Pac J Clin Oncol. 2015 Nov 4. doi: 10.1111/ajco.12418. [Epub ahead of print].
Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.
Hungria VT et al. Ann Hematol. 2015 Oct 30. [Epub ahead of print].
Plerixafor for stem cell mobilization: the current status.
Bilgin YM et al. Curr Opin Hematol. 2015 Nov 7. [Epub ahead of print].
Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.
Cerchione C et al. Eur J Haematol. 2015 Nov 21. doi: 10.1111/ejh.12705. [Epub ahead of print]